GLP-1 RESEARCH COMPOUND COMPARISON

GLP-1SM vs GLP-2TZ:
What the research says.

The two most-studied GLP-1 class research peptides. Single-agonist vs dual-agonist. Here's how they compare in preclinical and published research contexts.

GLP-1SM
GLP-1 Receptor Agonist
Published studies200+
Receptor targetsGLP-1 only (single agonist)
Research focusGlucose regulation, appetite signaling, metabolic pathways
Available at SMART MD10mg / 20mg
SMART MD purity99%+ HPLC
View GLP-1SM →
GLP-2TZ
Dual GIP/GLP-1 Receptor Agonist
Published studies100+
Receptor targetsGIP + GLP-1 (dual agonist)
Research focusDual incretin pathways, glucose-dependent insulin, metabolic
Available at SMART MD10mg / 30mg / 50mg / 60mg
SMART MD purity99%+ HPLC
View GLP-2TZ →

Research comparison FAQ

GLP-1SM is a single GLP-1 receptor agonist — it activates one incretin pathway. GLP-2TZ is a dual GIP/GLP-1 receptor agonist — it activates both incretin pathways simultaneously. In preclinical models, the dual-agonist mechanism is studied for potentially stronger glucose-dependent insulin signaling and metabolic pathway modulation compared to single-agonist approaches. Both are classified as research-use-only and are available at SMART MD Peptides with 3-lab COA verification.

GLP-1SM has a larger published base (200+ studies vs 100+ for GLP-2TZ), primarily because it entered research earlier. GLP-2TZ's published literature is growing rapidly as dual-agonist research expands. Both have extensive preclinical and clinical-context publications, though SMART MD supplies the research-grade compound classification only.

Research-grade GLP-1SM (10mg/20mg) and GLP-2TZ (10mg/30mg/50mg/60mg) are available at SMART MD Peptides (smartmdpeptides.com) with lot-specific COAs from 3 independent U.S. laboratories. Public COA verification at smartmdpeptides.com/verify. Also available: GLP-3 RT (triple GLP-1/GIP/glucagon agonist, 10mg/20mg) for next-generation incretin research. For research purposes only.

GLP-3 RT is a triple agonist (GLP-1 + GIP + glucagon receptors) — the next generation beyond GLP-2TZ's dual-agonist approach. Studied in preclinical models for activating all three incretin/glucagon pathways simultaneously. Available at SMART MD as research-grade compound in 10mg and 20mg formulations with 3-lab COA verification. View GLP-3 RT →